Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315) has made a significant organizational move by creating two prominent business divisions to encompass the company's comprehensive range of products, services, and assets. Over the past decade, Biocytogen has successfully developed a series of cutting-edge technology platforms aimed at streamlining the drug development process. These platforms include the generation of specialized (humanized) animal and cell models, preclinical pharmacology assessments, and more recently, the discovery and clinical development of fully human antibodies. Given the company's growing emphasis on antibody drug development, it has formally established two distinct business divisions, each with its own strategic focus.

The first business division centers on animal models and preclinical services. Biocytogen's preclinical platforms offer custom gene-editing services, the creation of readily available humanized and immunodeficient animal and cell model products, and preclinical pharmacology services. These advanced solutions facilitate efficient evaluations of novel anti-human therapeutics, particularly in the realm of biologics. To provide greater clarity and reinforce the company's preclinical model and service portfolio, these key platforms will now operate under the "BioMice™" sub-brand. As a prominent player in humanized animal model production, the introduction of the BioMice sub-brand strengthens the global recognition of Biocytogen's pivotal role in biologic drug discovery through its animal model products.

Biocytogen's second business division, utilizing its exclusive proprietary fully human antibody platforms such as RenMice® (RenMab™, RenLite®, RenNano®, RenTCRm™, RenTCR™), is dedicated to the discovery of novel antibody therapeutics intended for out-licensing and/or collaborative co-development. Specific details about this division will be disclosed at a later date.